- Home
- BASE vs JANX Comparison
BASE vs JANX Comparison
Compare BASE & JANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BASE
- JANX
- Stock Information
- Founded
- BASE 2011
- JANX 2017
- Country
- BASE United States
- JANX United States
- Employees
- BASE N/A
- JANX N/A
- Industry
- BASE EDP Services
- JANX Biotechnology: Pharmaceutical Preparations
- Sector
- BASE Technology
- JANX Health Care
- Exchange
- BASE Nasdaq
- JANX Nasdaq
- Market Cap
- BASE 1.3B
- JANX 1.4B
- IPO Year
- BASE 2021
- JANX 2021
- Fundamental
- Price
- BASE $24.34
- JANX $25.11
- Analyst Decision
- BASE Hold
- JANX Strong Buy
- Analyst Count
- BASE 16
- JANX 8
- Target Price
- BASE $22.97
- JANX $90.63
- AVG Volume (30 Days)
- BASE 511.9K
- JANX 895.9K
- Earning Date
- BASE 09-03-2025
- JANX 08-07-2025
- Dividend Yield
- BASE N/A
- JANX N/A
- EPS Growth
- BASE N/A
- JANX N/A
- EPS
- BASE N/A
- JANX N/A
- Revenue
- BASE $214,662,000.00
- JANX $439,000.00
- Revenue This Year
- BASE $12.42
- JANX N/A
- Revenue Next Year
- BASE $14.20
- JANX $1,470.83
- P/E Ratio
- BASE N/A
- JANX N/A
- Revenue Growth
- BASE 12.76
- JANX N/A
- 52 Week Low
- BASE $12.78
- JANX $21.97
- 52 Week High
- BASE $25.16
- JANX $71.71
- Technical
- Relative Strength Index (RSI)
- BASE 67.91
- JANX 53.07
- Support Level
- BASE $24.29
- JANX $23.96
- Resistance Level
- BASE $24.41
- JANX $25.93
- Average True Range (ATR)
- BASE 0.07
- JANX 1.55
- MACD
- BASE -0.10
- JANX 0.08
- Stochastic Oscillator
- BASE 73.08
- JANX 69.31
About BASE Couchbase Inc.
Couchbase Inc provides a modern cloud database that offers the robust capabilities required for business-critical applications on a scalable and available platform. It empower developers and architects to build, deploy and run mission-critical applications. Couchbase delivers a high-performance, flexible and scalable modern database that runs across the data center and any cloud. Geographically, the company generates a majority of its revenue from the United States.
About JANX Janux Therapeutics Inc.
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. Its proprietary technology has enabled the development of two distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.